Monday, February 13, 2012
The move means that the use of Truvada as a way to reduce HIV risk could be approved by June 15, rather than face a standard 10-month agency review.
If approved, Truvada would be the first drug for uninfected people to reduce the risk of acquiring HIV.
But Foster City-based Gilead (NASDAQ: GILD) faces a rough road on its way to winning approval of Truvada as a preventative treatment. At least one AIDS patient advocacy group, the AIDS Healthcare Foundation in Los Angeles, has opposed the plan.